On April 28, the FDA approved a generic version of the nasal spray AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE manufactured by Apotex Corp., representing significant market competition that is expected to drive down pricing for allergy relief treatments. This approval expands the generic landscape for high-demand inhaled and nasal products, potentially pressuring brands to maintain pricing strategies or accelerate their own biosimilars timelines.